Loading interface...

Ibset 5 mcg Tablet

Manufactured byZydus Cadila
ContainsRamosetron
Description
Ibset 5 mcg Tablet is an antiemetic drug used to prevent nausea and vomiting associated with cancer chemotherapy. It is also used for the treatment of diarrhea associated with irritable bowel syndrome. This medicine is not recommended for use in patients less than 18 years of age.

Side effects

Major & minor side effects for Ibset 5 mcg Tablet

  • Headache
  • Constipation
  • Skin rash
  • Redness of skin
  • Hiccups
  • Wheezing
  • Difficulty in breathing
  • Chest discomfort

Uses of Ibset 5 mcg Tablet

What is it prescribed for?

  • Chemotherapy induced nausea and vomiting
  • Diarrhea associated with Irritable Bowel Syndrome
Read More
Concerns

Commonly asked questions

  • How long does it take for this medicine to take effect?
    The amount of time required for this medicine to shows its action is not clinically established.
  • How long do the effects of this medicine last?
    The effect of this medicine lasts for an average duration of 48 hours.
  • Is it safe to consume alcohol while taking this medicine?
    Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
  • Is this a habit forming medicine?
    No habit forming tendency has been reported.
  • Can this medicine be taken during pregnancy?
    This medicine is not recommended for use in pregnant women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before taking or receiving this medicine.
  • Can this medicine be taken while breast-feeding?
    This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before taking or receiving this medicine.

Allergy

This medicine is not recommended for use in patients with a known allergy to Ramosetron or any other inactive ingredients present along with it.
Warnings for special population

Pregnancy

This medicine is not recommended for use in pregnant women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before taking or receiving this medicine.

Breast-feeding

This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before taking or receiving this medicine.
General warnings

Use in Children

This medicine is not recommended for use in patients below 18 years of age since the safety and efficacy of use are not clinically established.

Constipation

This medicine should be used with caution in patients with constipation due to the increased risk of worsening of the patient's condition. Appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary in some cases.

Other medicines

Ibset 5 mcg Tablet may interact with many other medicines and may cause severe adverse effects. Hence, it is advised that you inform the doctor about all your current medicines including any herbs and supplements before beginning treatment with this medicine.

Liver Disease

This medicine should be used with caution in patients with liver diseases due to the increased risk of adverse effects. Regular monitoring of liver function tests is necessary for such patients. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.

Kidney Disease

This medicine should be used with caution in patients with kidney diseases due to the increased risk of adverse effects. Regular monitoring of kidney function tests is necessary for such patients. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.

Missed Dose

Oral forms: Take the missed dose as soon as you remember. If it is almost the time for your next dose, skip the missed dose. Do not double your dose to make up for the missed one. Injection: Since this medicine is administered by a qualified health care professional in the clinical or hospital setting, the likelihood of a missed dose is very low.

Overdose

Oral forms: Seek emergency medical attention or contact your doctor in case of an overdose. Injection: Since this medicine is administered in the hospital setting by a qualified healthcare professional, the likelihood of an overdose is very less. However, emergency medical treatment will be initiated by the doctor if an overdose is suspected.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol

Description

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

Instructions

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
Interaction with Medicine

Carbamazepine

Desloratidine

Fluvoxamine

Darifenacin

Disease interactions

Disease

Information not available.
Food interactions
Information not available.
Lab interactions
Information not available.
Oral forms: Take this medicine with or without food. Do not take in larger amounts than advised/prescribed. Consult the doctor if you experience any undesirable effects. Do not stop taking the medicine before completion of the course/without consulting your doctor. Injection: This medicine is usually administered in the clinical/hospital setting under the supervision of a qualified healthcare professional. Follow all the instructions given by your doctor. Inform the doctor if you have a known allergy to this medicine. Report all your current medicines as well as your medical conditions to the doctor before receiving this medicine.
Miscelleneous

Can be taken with or without food, as advised by your doctor

To be taken as instructed by doctor

Does not cause sleepiness

How it works
This medicine blocks the action of certain chemicals in the body that are responsible for causing nausea and vomiting.
Legal Status

Approved

Unknown

Approved

Unknown

Classification

Category

Antiemetics, 5HT3 receptor antagonists, Miscellaneous Antidiarrheals

Schedule

Schedule H

Effect of ramosetron in female patients with irritable bowel syndrome with diarrhea: a phase III long-term study. - PubMed - NCBI [Internet]. Ncbi.nlm.nih.gov. 2018 [cited 10 September 2018]. Available from:

https://www.ncbi.nlm.nih.gov/pubmed/26800997

Long-term efficacy and safety of ramosetron in the treatment of diarrhea-predominant irritable bowel syndrome. - PubMed - NCBI [Internet]. Ncbi.nlm.nih.gov. 2018 [cited 10 September 2018]. Available from:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3728153/

Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials. - PubMed - NCBI [Internet]. Ncbi.nlm.nih.gov. 2018 [cited 10 September 2018]. Available from:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5759234/

Ramosetron - DrugBank [Internet]. Drugbank.ca. 2018 [cited 10 September 2018]. Available from:

https://www.drugbank.ca/drugs/DB09290
Loading related questions...
Something doesn’t feel right?
Report an error

Information on this page was last updated on 11 Jun 2019

Disclaimer

We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.